drugset / Trial / NCT01638000

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

NCT01638000

Phase 3 Completed 1887 enrolled Astellas Pharma Europe Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.

Timeline

Start
2012-06-12
Primary completion
2013-04-24
Completion
2013-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 50 mg Oral
Comparator Solifenacin Small molecule 5 mg Oral

Indications